Deseret Laboratories is a full service contract manufacturer of solid dose tablets/capsules and powders to nutraceutical (dietary supplement) products and OTC drugs with a specialty in Effervescents. We service the custom, direct marketing and retail industries. DLI also provides quality manufacturing of intermediates as granulations and Wurster coated API's or Nutritional powders. DLI has a full service R&D facility to assist customers in transforming their formulas to full-scale production. DLI also sells direct to the retail industry as OTC drugs, specializing in the effervescent products.
Texas BioGene Inc. (TBG) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of nucleic acid testing kits and services. Founded in Texas, USA (1999), TBG is one of the leading providers of quality HLA Typing Kits for immune matching of bone marrow, cord blood and solid organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China.
Due to it's unparalleled performance in immune matching ability, nucleic acid testing is becoming an essential tool in helping the clinician with critical transplant decisions. TBG is continually pushing to the forefront of nucleic acid testing for diagnostics. From the extraction of nucleic acids, amplification and detection of infectious diseases, genotyping and viral load testing, TBG is commited to expanding the applications of our core technology. To this end TBG's EZbead Systems for automated nucleic acid extraction based on magnetic bead technology have been introduced to help make nucleic acid diagnostics accessible to laboratories worldwide.
Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.
Pharmaron is a contract research organization (CRO).
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services
CRO - Contract Research Organization
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
in vitro Biology
in vitro Screening
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
in vitro ADME
in vivo PK
Drug Product Manufacturing
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
Microdosing Phase 0
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."
AfaSci, Inc., a San Francisco Bay Area biotech company committed to enhancing health care by conducting R&D in both Biotechnology and Therapeutics. Our bioengineering team has designed, produced and been marketing an in vivo drug screening platform, SmartCageTM. This system enables automated, and objective assessment of drug effects on rodent behavior and increases throughput of phenotyping of transgenic animals. Elevating our proprietary platform and well-established electrophysiological techniques, AfaSci’s scientists have been discovering IND drug candidates targeting ion channels and GPCR for the treatment of CNS disorders, especially neuropathic pain, epilepsy and Alzheimer’s disease.